Swiss biotech company Memo Therapeutics raises $15.5m in Series B round
Memo Therapeutics has raised CHF14 million ($15.56 million) in a Series B financing round towards the clinical development of potent antibodies for the immunotherapy of ... Read More
Northway Biotechpharma to manufacture Memo’s Covid1-9 drug MTX-COVAB
Memo Therapeutics (MTx), a Swiss biotech company, has entered into a partnership with Northway Biotechpharma, under which the latter will manufacture the former's MTX-COVAB - ... Read More